DIRS.INFO The most relevant business & tech news

☆ Ozempic and Wegovy may help curb alcohol addiction, study suggests
▼ + stars: | 2024-11-13 | by ( Kaitlin Sullivan | Kaitlin Sullivan Is A Contributor For Nbcnews.Com Who Has Worked With Nbc News Investigations. She Reports On Health | Science | ) www.nbcnews.com time to read: +5 min

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA Psychiatry suggests. Just over 28 million adults in the U.S. have alcohol addiction, according to the National Institute on Alcohol Abuse and Alcoholism. Several other studies have examined drinking habits among people taking GLP-1 drugs who do not have alcohol use disorder. Around 75,000 people in the study used some type of medication to treat alcohol use disorder. So far, the clearest results have come from studies on alcohol addiction — but there is still a lot to understand.

Persons: Ozempic, ”, Alex DiFeliceantonio, Markku, “, ” DiFeliceantonio, Christian Hendershot, Hendershot, Lähteenvuo, DiFeliceantonio, ” Hendershot Organizations: Psychiatry, National Institute, Alcohol, Biomedical Research Institute, Niuvanniemi Hospital, University of Southern California Institute for Addiction Science Locations: Sweden, U.S, Virginia, Finland, Swedish

☆ Semaglutide linked to reduced arthritis knee pain in people with obesity, study finds
▼ + stars: | 2024-10-30 | by ( Kaitlin Sullivan | Kaitlin Sullivan Is A Contributor For Nbcnews.Com Who Has Worked With Nbc News Investigations. She Reports On Health | Science | ) www.nbcnews.com time to read: +4 min

People who lost a significant amount of weight with semaglutide saw major improvements in osteoarthritis knee pain, research published Wednesday in the New England Journal of Medicine finds. “Any sort of dramatic weight loss will relieve pain,” Bliddal said. In another study led by Bliddal, people with knee osteoarthritis were given an older weight loss drug, liraglutide. The average BMI in that study was about 32, lower than the average in the new study. Most of the people in the study had a BMI over 35, and nearly half had a BMI of over 40.

Persons: semaglutide, Wegovy —, ”, Daniel Wiznia, Henning Bliddal, David Felson, That’s, ” Wiznia, ” Bliddal, Bliddal, liraglutide, Felson, Wiznia, “, ” Felson Organizations: New England, of Medicine, Novo Nordisk, Yale Medicine, University of Copenhagen, Boston University Chobanian, Avedisian School of Medicine, BMI, Food and Drug Administration Locations: Denmark

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia. Another study, published in August, found that semaglutide appeared to cut the risk of dementia in people with Type 2 diabetes. Type 2 diabetes is a risk factor for dementia and Alzheimer’s. The study found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The biggest difference was seen when comparing patients who took semaglutide to those who took insulin: Semaglutide patients had a 70% lower risk of Alzheimer’s, the study found.

Persons: —, semaglutide, ”, Stephen Salloway, ” Salloway, Rong Xu, liraglutide, Xu, ” Xu, they’re, Salloway, they’ve, Donna Wilcock, there’s, ” Wilcock, Dr, Alberto Espay, Espay, What’s, “, ” Espay Organizations: Alzheimer’s Association, Conference, Novo Nordisk, Warren Alpert Medical, Brown University, Center, Artificial Intelligence, Case Western Reserve University School of Medicine, Drug Administration, ”, Alzheimer’s, Indiana University School of Medicine, University of Cincinnati College of Medicine Locations: Novo, Rhode Island, Ohio

The FDA’s announcement on Oct. 2 declaring the shortage over meant that compounding pharmacists had to stop filling tirzepatide prescriptions. Simone Williams, 50, of Spartanburg, S.C was prescribed compounded tirzepatide in June 2023 after her Mounjaro savings card expired. Williams began taking compounded tirzepatide for weight loss last year after her Mounjaro savings card expired. Tirzepatide was on the FDA’s drug shortage list for nearly two years. ‘Peace of mind’Meanwhile, patients and compounding pharmacists are celebrating the FDA decision to allow tirzepatide compounding to continue.

Persons: Lilly’s, Mounjaro, Zepbound, semaglutide, Wegovy, drugmakers, tirzepatide, “, Simone Williams, S.C, Simone Williams Simone Williams, Williams, ” Williams, she’s, I’m, ”, Lilly, Michael Ganio, Ganio, Dr, Christopher McGowan, ” McGowan, ” Lilly, Jared Shapiro, ’ ” Shapiro, Elizabeth Kenly, ” Kenly, Kenly Organizations: Drug Administration, FDA, Association, American Society of Health, System, Outsourcing, Alliance, Pharmacy, APC Locations: Spartanburg, Spartanburg , South Carolina, U.S, Cary , North Carolina, Graham , North Carolina

☆ Nearly half of online pharmacies selling weight loss drugs are operating illegally, study finds
▼ + stars: | 2024-08-02 | by ( Liz Szabo | Liz Szabo Is An Independent Health | Science Journalist. Her Work Has Won Multiple National Awards. One Of Her Investigations Led To A New State Law In Virginia. | ) www.nbcnews.com time to read: +8 min

Consumers who try to buy popular weight loss drugs online without a prescription risk being scammed or receiving unsafe products, a new study shows. Shortages of the popular weight loss medication, which belongs to a class of drugs called GLP-1s, have led to “a black market of illegal knockoffs,” said Dr. Christopher McGowan, the founder, medical director and research director of True You Weight Loss, a weight loss clinic in Cary, North Carolina. Medicare doesn’t cover the drugs when prescribed for weight loss, and many state Medicaid plans heavily restrict coverage. Online scamsSome websites purporting to be online pharmacies take consumers’ money but never deliver the medications, according to the study. Consumers won’t get that sort of care if they buy drugs online without seeing a health care provider.

Persons: ”, Tim Mackey, Christopher McGowan, McGowan, semaglutide, won’t, Mackey, ” McGowan, “, Shabbir Safdar, Scott Brunner, Safdar, Brunner, Consumers won’t, it’s Organizations: Nordisk’s, University of California, Global Health, Data Institute, University of Pecs, FDA, Manufacturers can’t, Medicare, JAMA, Food and Drug Administration, semaglutide, Novo Nordisk, telltale, Partnership, Safe Medicines, Alliance, Pharmacy, Consumers Locations: San Diego, Hungary, Cary , North Carolina, U.S

☆ Novo Nordisk's Wegovy wins EU backing for reducing heart risks
▼ + stars: | 2024-07-26 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand the medicine's use to include reducing the rise of serious heart events in overweight and obese adults. "The SELECT data demonstrated that in addition to helping people manage their weight, Wegovy has the potential to protect lives by reducing the risks of major adverse cardiovascular events." Novo Nordisk said it expects to implement the label update within a month. The company's CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential."

Persons: Wegovy, —, Martin Holst Lange, Roche, Thomas Schinecker Organizations: Novo Nordisk, Novo, European Medical Agency, U.S . Food, Drug Administration Locations: Danish, U.S, Swiss

☆ Mounjaro leads to significantly more weight loss than Ozempic, study suggests
▼ + stars: | 2024-07-08 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +4 min

CNN —People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. But 82% of people taking tirzepatide reached this important clinical benchmark, compared with about 67% of those taking semaglutide. Average weight loss was also consistently higher among those taking tirzepatide over time. And by one year, average weight loss was nearly double for those taking tirzepatide — more than 11%, compared with about 6% for those taking semaglutide. According to the new study, individuals with type 2 diabetes had less significant weight loss than those without a diagnosis — but average weight loss was still greater among those taking tirzepatide.

Persons: tirzepatide, Eli Lilly, ”, Dr, Sanjay Gupta, CNN’s Brenda Goodman Organizations: CNN, US Food and Drug Administration, Novo Nordisk, semaglutide, FDA, CNN Health Locations: Truveta

☆ European drugs regulator to review Wegovy, Ozempic following reports of suicidal thoughts
▼ + stars: | 2023-07-10 | by ( Anmar Frangoul | ) www.cnbc.com time to read: +1 min

The European Medicines Agency said Monday it would undertake a review into a number of drugs used to treat obesity and diabetes after it was reported some patients experienced thoughts of suicide or self-harm. "The review is being carried out in the context of a signal procedure raised by the Icelandic Medicines Agency following three case reports," the EMA said. The EMA said the case reports "included 2 cases of suicidal thoughts, one following the use of Saxenda and one after Ozempic. "The semaglutide-containing medicine Wegovy and the liraglutide-containing medicine Saxenda are authorised for weight loss, together with diet and physical activity," the EMA said. "Suicidal behaviour is not currently listed as a side effect in the EU product information of these medicines," the EMA said.

Organizations: Novo Nordisk, European Medicines Agency, Icelandic Medicines Agency, Saxenda Locations: Danish

☆ Credit Suisse sees Eli Lilly headed higher as Mounjaro users espouse weight loss drug on social media
▼ + stars: | 2023-06-15 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Credit Suisse analyst Trung Huynh has combed through social media and is impressed by the awareness — and demand — for GLP-1 medications such as Eli Lilly 's Mounjaro. Among those observations are reports of other potential benefits that patients taking Mounjaro, or tirzepatide, are seeing. Others taking the drug reported benefits such as a reduction in addiction behaviors such as smoking, drinking, gambling and shopping, among other things. However, this may be a function of patients who are trying to use Mounjaro off-label for obesity, he said. Credit Suisse has an outperform rating on Lilly shares, with a $490 price target, which implies more than 9% upside from where Lilly shares closed Wednesday.

Persons: Trung Huynh, Eli Lilly, Huynh, Mounjaro, agonism, Lilly hasn't, semaglutide —, Lilly, —, Michael Bloom Organizations: Credit Suisse, Food and Drug Administration, Novo Nordisk

☆ Ozempic prices are soaring online in China thanks to unofficial price gouging, with medics scrambling to keep up with demand, reports say
▼ + stars: | 2023-06-07 | by ( Mia Jankowicz | ) www.businessinsider.com time to read: +2 min

The Ozempic craze has hit China, causing shortages and price hikes, reports say. Poeple using it to lose weight has caused shortages for Type 2 diabetes patients, doctors say. People in China are rushing to buy up Ozempic for weight loss, causing a boom in prices and leaving shortages for diabetes patients, according to reports. Semaglutide — marketed as Wegovy when used for weight loss in the US — has proven in some studies to be effective in causing weight loss. The platform has also deleted thousands of posts by people sharing their experiences with the drug, CNN reported.

Persons: semaglutide, —, Semaglutide —, It's Organizations: Bloomberg, CNN, China, Huadong, Novo Nordisk Locations: China, Guangzhou, Canada, Mexico

☆ Why buzzy weight-loss drugs such as Ozempic and Wegovy cost so much more in the US
▼ + stars: | 2023-05-10 | by ( ) www.businessinsider.com time to read: +4 min

Trendy weight-loss drugs cost much more in the US than in other countries. The price of semaglutide, the drug sold as Wegovy, was three times higher in the US than in the UK. If you're searching for affordable weight-loss drugs, you may be better off looking outside of the US. New weight-loss drugs are unaffordableGetty ImagesWegovy and Ozempic are part of a class of weight-loss drugs known as GLP-1 agonists that have soared in popularity in recent months. Drug prices are highest in the USThe variation in prices for weight-loss drugs across the world is striking.

☆ The 13 startups to watch in the $100 billion market for buzzy new weight-loss drugs like Ozempic
▼ + stars: | 2023-04-11 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +3 min

Healthcare startups are launching to prescribe weight-loss drugs such as Ozempic. They're chasing what's projected to be a $100 billion market for the drugs. Venture-backed health startups are vying for a piece of the booming market for new prescription drugs designed to help with weight loss. Many startups offering weight-loss drugs have flooded social media platforms with ads for the shots. Insider rounded up 13 venture-backed startups competing for customers in the lucrative GLP-1 weight-loss market, listed from least to most funding raised.

☆ 13 startups vying for a slice of the $100 billion market for buzzy new weight-loss drugs
▼ + stars: | 2023-04-05 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +3 min

Search resuls for: "Semaglutide —"

13 mentions found